QURE — uniQure N.V.

Summary of uniQure Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $16.1 million for the year ended December 31, 2025, down from $27.1 million in 2024, primarily due to a $10.7 million decrease in collaboration revenue and a $6.1 million drop in contract manufacturing revenues.
• R&D Expenses: $140.7 million, a slight decrease from $143.8 million in 2024, attributed to reduced employee and facility costs following the divestment of the Lexington manufacturing operation.
• SG&A Expenses: Increased to $65.5 million from $52.7 million, driven by higher professional fees related to AMT-130 commercialization efforts.
• Cash Position: $622.5 million as of December 31, 2025, significantly up from $367.5 million in 2024, bolstered by $404.2 million raised through public offerings.
• Cash Runway: Expected to fund operations into the second half of 2026.

2. Strategic Updates and Business Highlights

• AMT-130 for Huntington's Disease: Reported significant 3-year data showing a 75% slowing of disease progression. However, the FDA indicated that this data might not suffice for a Biologics License Application (BLA) submission.
• Regulatory Engagement: Plans to conduct a Phase III randomized, double-blind sham-controlled study as recommended by the FDA, with a Type B meeting scheduled for Q2 2026 to discuss the study design.
• Pipeline Development: Progress in other programs, including AMT-191 for Fabry disease and AMT-260 for temporal lobe epilepsy, with promising early data reported.

3. Forward Guidance and Outlook

• 2026 Priorities: Focus on engaging with regulatory authorities to define pathways for AMT-130, advancing pipeline programs, and generating high-quality data.
• Data Updates: Plans to amend the statistical analysis plan for AMT-130 to include a 4-year analysis, expected in Q3 2026.

4. Bad News, Challenges, or Points of Concern

• Regulatory Challenges: The FDA's requirement for a Phase III study poses significant logistical and ethical concerns, particularly regarding patient burden and the feasibility of a sham-controlled design.
• Revenue Decline: Notable decrease in overall revenue and collaboration income raises concerns about future financial performance.
• Increased SG&A Expenses: Rising costs associated with commercialization efforts could pressure profitability.

5. Notable Q&A Insights

• Regulatory Flexibility: Management emphasized the need for regulatory flexibility given the urgency of unmet needs in Huntington's disease and the strong data supporting AMT-130.
• Patient Community Advocacy: The importance of patient advocacy in influencing regulatory discussions was highlighted, with ongoing efforts to engage with the HD community.
• Study Design Feasibility: Discussions around the feasibility of a sham-controlled study indicated potential ethical concerns and the need for careful consideration of patient risks.
• Commercial Opportunities: While exploring ex-U.S. markets, management noted it’s premature to estimate commercial potential, but they are learning from past examples in the industry.

Overall, while uniQure has a strong financial position and promising data for its therapies, significant regulatory hurdles and declining revenues present challenges that will require careful navigation in the coming year.